Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: Systematic literature review and meta-analysis of randomised controlled trials

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Conway, Richard ^a,b   Low, Candice ^c   Coughlan, Robert J ^a   O'Donnell, Martin J ^b   Carey, John J ^a,b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c Stroke and Hypertension Unit   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; FOLIC ACID; METHOTREXATE; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

AGE DISTRIBUTION; ASTHMA; COUGHING; DATA ANALYSIS; DIET SUPPLEMENTATION; DISEASE DURATION; DRUG FATALITY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG EMBOLISM; LUNG INFECTION; MANTEL HAENSZEL RANDOM METHOD; META ANALYSIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; RISK ASSESSMENT; SEX RATIO; SINUSITIS; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY TRACT INFECTION; ADULT; ARTHRITIS, PSORIATIC; CHEMICALLY INDUCED; INFLAMMATORY BOWEL DISEASES; RISK FACTOR;

ADULT; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LUNG DISEASES; METHOTREXATE; PSORIASIS; RISK FACTORS;

EID: 84926152386     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1269     Document Type: Review

References (37)

1. Food and Drug Administration. Methotrexate prescribing information. 2014. www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 011719s117lbl.pdf.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
4. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
5. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64.
6. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
7. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62.
8. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensityadjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013;65:334-42.
9. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
10. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994;53:434-9.
11. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26(5 Suppl 51):S35-61.
12. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583-91.
13. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
14. Kremer JM, Alarcón GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
15. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997;156(2 Pt 1):528-35.
16. Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 2008;47:1647-50.
17. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 2014;66:803-12.
18. Review Manager (RevMan). Version 5.1. Nordic Cochrane Centre, Cochrane Collaboration, 2011.
19. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. www.cochrane-handbook.org.
20. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-8.e1.
21. Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012;167:649-57.
22. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368-77.
23. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365:1586-96.
24. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66.
25. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
26. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
27. Kluger N, Bessis D, Guillot B, Girard C. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasisassociated aseptic pneumonitis). J Am Acad Dermatol 2011;64:1154-8.
28. Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997;16:296-304.
29. Ameen M, Taylor DA, Williams IP, Wells AU, Barkert JN. Pneumonitis complicating methotrexate therapy for pustular psoriasis. J Eur Acad Dermatol Venereol 2001;15:247-9.
30. Lee MA, Hutchinson DG. HRCT-proven leflunomide pneumonitis in a patient with psoriatic arthritis and normal lung function tests and chest radiography. Rheumatology (Oxford) 2010;49:1206-7.
31. Margagnoni G, Papi V, Aratari A, Triolo L, Papi C. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis 2010;4:211-4.
32. Hotermans G, Benard A, Guenanen H, Demarcq-Delerue G, Malart T, Wallaert B. Nongranulomatous interstitial lung disease in Crohn's disease. Eur Respir J 1996;9:380-2.
33. Balestra DJ, Balestra ST, Wasson JH. Ulcerative colitis and steroidresponsive, diffuse interstitial lung disease. JAMA 1988;260:62-4.
34. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013;7:107-12.
35. Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol 2011;65:1135-44.
36. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research: interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999;319:312-5.
37. Concato J, Shah N, Horwitz RI. Randomised, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;343:1887-92.